Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ike, O
Right arrow Articles by Ikada, Y
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ike, O
Right arrow Articles by Ikada, Y

Chest, Vol 99, 911-915, Copyright © 1991 by American College of Chest Physicians

ARTICLES

Treatment of malignant pleural effusions with doxorubicin hydrochloride- containing poly(L-lactic acid) microspheres

O Ike, Y Shimizu, S Hitomi, R Wada and Y Ikada
Research Center for Biomedical Engineering, Kyoto University, Japan.

For the treatment of malignant pleural effusions, we prepared doxorubicin hydrochloride (Adriamycin)-containing poly(L-lactic acid) microspheres (ADR-MS). In vitro, 50 percent and 100 percent release times of ADR from ADR-MS were 6.3 and 20 days, respectively. After intrapleural administration of ADR-MS for seven patients at an ADR dose of 40 mg, ADR was detected in the effusions for more than two weeks; however, ADR concentrations in serum were very small, consistent with minimal transpleural absorption of ADR. These results indicated the slow release of ADR into the pleural cavity. Furthermore, the amount of drained ADR was less than a few percent of the administered dose. In some cases, malignant cells in the effusion disappeared after the treatment. No complications related to the procedure occurred, and the patients developed no systemic symptoms. One patient died after four months, and the other six patients are alive after 21 to 31 months without reaccumulation of the effusion. The local administration of ADR- MS produces a localized high and systemic low concentration of ADR, which could potentially improve the patient's quality of life.


This article has been cited by other articles:


Home page
 ChestHome page
P. A. Kvale, M. Simoff, and U. B. S. Prakash
Palliative Care
Chest, January 1, 2003; 123(1_suppl): 284S - 311S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. Shoji, F. Tanaka, K. Yanagihara, K. Inui, and H. Wada
Phase II Study of Repeated Intrapleural Chemotherapy Using Implantable Access System for Management of Malignant Pleural Effusion
Chest, March 1, 2002; 121(3): 821 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
V.B. Antony, R. Loddenkemper, P. Astoul, C. Boutin, P. Goldstraw, J. Hott, F. Rodriguez Panadero, and S.A. Sahn
Management of malignant pleural effusions
Eur. Respir. J., August 1, 2001; 18(2): 402 - 419.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Management of Malignant Pleural Effusions
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1987 - 2001.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American College of Chest Physicians.